Eric Assénat

23.3k total citations · 3 hit papers
176 papers, 10.2k citations indexed

About

Eric Assénat is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eric Assénat has authored 176 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 66 papers in Hepatology and 51 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eric Assénat's work include Hepatocellular Carcinoma Treatment and Prognosis (60 papers), Pancreatic and Hepatic Oncology Research (37 papers) and Colorectal Cancer Treatments and Studies (36 papers). Eric Assénat is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (60 papers), Pancreatic and Hepatic Oncology Research (37 papers) and Colorectal Cancer Treatments and Studies (36 papers). Eric Assénat collaborates with scholars based in France, Italy and United States. Eric Assénat's co-authors include Marc Ychou, Rosine Guimbaud, Jean‐Luc Raoul, Françoise Desseigne, Christelle de la Fouchardière, Jean‐Baptiste Bachet, Michel Ducreux, Olivier Bouché, Y. Bécouarn and Antoine Adenis and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Eric Assénat

168 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

2011 5.5k citations Marc Ychou, Eric Assénat et al. profile →
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

2014 449 citations Eric Assénat, Stéphane Cattan et al. profile →
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

2023 136 citations Eric Assénat et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric Assénat France	38	7.2k	2.7k	2.5k	2.1k	2.0k	176	10.2k
Jean‐Luc Van Laethem Belgium	44	7.9k 1.1×	2.2k 0.8×	3.2k 1.3×	3.4k 1.6×	1.6k 0.8×	275	10.4k
Rosine Guimbaud France	34	7.7k 1.1×	2.4k 0.9×	2.5k 1.0×	2.3k 1.1×	2.0k 1.0×	178	9.5k
Robert R. McWilliams United States	46	5.9k 0.8×	1.9k 0.7×	1.9k 0.8×	1.9k 0.9×	1.1k 0.5×	206	8.4k
Shoji Nakamori Japan	55	4.4k 0.6×	2.0k 0.8×	1.9k 0.8×	2.7k 1.3×	1.5k 0.8×	276	10.1k
Howard S. Höchster United States	56	8.1k 1.1×	1.8k 0.7×	3.3k 1.4×	1.8k 0.8×	1.1k 0.5×	342	12.0k
Jean‐Baptiste Bachet France	39	11.4k 1.6×	4.1k 1.5×	4.2k 1.7×	2.7k 1.3×	2.0k 1.0×	213	13.5k
Antoine Adenis France	40	10.4k 1.4×	2.9k 1.1×	5.4k 2.2×	4.0k 1.9×	1.7k 0.8×	213	14.2k
Junji Furuse Japan	54	6.6k 0.9×	2.2k 0.8×	3.7k 1.5×	4.7k 2.2×	2.9k 1.4×	421	12.7k
Ghassan K. Abou‐Alfa United States	51	5.2k 0.7×	2.1k 0.8×	3.0k 1.2×	4.5k 2.1×	1.8k 0.9×	345	11.4k
Tsutomu Fujii Japan	51	5.2k 0.7×	1.4k 0.5×	2.9k 1.2×	3.4k 1.6×	1.5k 0.8×	330	8.7k

Countries citing papers authored by Eric Assénat

Since Specialization

Citations

This map shows the geographic impact of Eric Assénat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Assénat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Assénat more than expected).

Fields of papers citing papers by Eric Assénat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Assénat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Assénat. The network helps show where Eric Assénat may publish in the future.

Co-authorship network of co-authors of Eric Assénat

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Assénat. A scholar is included among the top collaborators of Eric Assénat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Assénat. Eric Assénat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Anzala, Omu, et al.. (2025). Placental malaria infection is associated with downregulation of STAT-6 and ANG-1 in decidual macrophages. Frontiers in Immunology. 16. 1497936–1497936.

Camus, Marine, Geoffroy Vanbiervliet, Robert Benamouzig, et al.. (2025). Prospective assessment of learning curve and impact of intensive versus progressive training in colonoscopy competence among French residents. BMC Medical Education. 25(1). 367–367.

Merle, Philippe, Jean-Marie Péron, Karine Le Malicot, et al.. (2024). Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 42(16_suppl). e16195–e16195. 1 indexed citations

Santoro, Armando, Eric Assénat, Thomas Yau, et al.. (2024). A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma. JHEP Reports. 6(4). 101021–101021. 5 indexed citations

Müller, Marie, Lorraine Blaise, René Gerolami, et al.. (2023). Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors. Digestive and Liver Disease. 55(7). 938–944. 2 indexed citations

Pageaux, Georges‐Philippe, et al.. (2023). Circulating Tumor DNA Clinical Applications in Hepatocellular Carcinoma: Current Trends and Future Perspectives. Clinical Chemistry. 70(1). 33–48. 5 indexed citations

Gigante, Elia, Mohamed Bouattour, Hélène Regnault, et al.. (2023). Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study. Journal of Hepatology. 78. S577–S577. 1 indexed citations

Cassinotto, Christophe, Erika Nogué, Fabrizio Panaro, et al.. (2023). Life expectancy of patients with hepatocellular carcinoma according to the upfront treatment: A nationwide analysis. Diagnostic and Interventional Imaging. 104(4). 192–199. 7 indexed citations

Delaye, Matthieu, Eric Assénat, Emmanuel Boleslawski, et al.. (2022). État des lieux des pratiques de prise en charge des cancers des voies biliaires en France : résultats de l'enquête nationale ACABi. Bulletin du Cancer. 109(11). 11S3–11S10. 2 indexed citations

10.

Herrero, Astrid, Gianluca Cassese, Eric Assénat, et al.. (2022). Progression of AFP SCORE is a Preoperative Predictive Factor of Microvascular Invasion in Selected Patients Meeting Liver Transplantation Criteria for Hepatocellular Carcinoma. Transplant International. 35. 10412–10412. 13 indexed citations

11.

Aouinti, Safa, Marie Dupuy, Eric Assénat, et al.. (2022). Survival after Multimodal Treatment Including Surgery for Metastatic Esophageal Cancer: A Systematic Review. Cancers. 14(16). 3956–3956. 7 indexed citations

12.

Guiu, Boris, Eric Assénat, Fabrizio Panaro, et al.. (2022). Prolonged Survival after Recurrence in HCC Resected Patients Using Repeated Curative Therapies: Never Give Up!. Cancers. 15(1). 232–232. 8 indexed citations

13.

Castan, Florence, Eric Assénat, Boris Guiu, et al.. (2021). Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. Cancers. 13(19). 4853–4853. 5 indexed citations

14.

Assénat, Eric, Mohamed Bouattour, Louise Gauthier, et al.. (2021). 48P (BREGO) Regorafenib combined with modified m-GEMOX in patients with advanced biliary tract cancer (BTC): A phase II randomized trial. Annals of Oncology. 32. S376–S377. 4 indexed citations

15.

Quantin, Xavier, Jean‐Luc Faillie, C. Lesage, et al.. (2021). Gestion des toxicités induites par les inhibiteurs de checkpoint immunologique : données de la réunion de concertation pluridisciplinaire « ToxImmun » en Occitanie Est. La Revue de Médecine Interne. 42(5). 310–319. 4 indexed citations

16.

Guiu, Boris, P. Chevallier, Eric Assénat, et al.. (2019). Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. Radiology. 291(3). 801–808. 27 indexed citations

17.

Allimant, Carole, Marilyne Kafrouni, Christophe Cassinotto, et al.. (2018). Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology. 29(12). 1662–1670.e4. 48 indexed citations

18.

Cayrefourcq, Laure, Thibault Mazard, Simon A. Joosse, et al.. (2015). Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. Cancer Research. 75(5). 892–901. 284 indexed citations

19.

Assénat, Eric, Simon Thézenas, Nicolas Flori, et al.. (2011). Prophylactic Percutaneous Endoscopic Gastrostomy in Patients With Advanced Head and Neck Tumors Treated by Combined Chemoradiotherapy. Journal of Pain and Symptom Management. 42(4). 548–556. 41 indexed citations

20.

Assénat, Eric, Frédéric Bibeau, D. Azria, et al.. (2007). The value of endoscopic rectal ultrasound in predicting the lateral clearance and outcome in patients with lower-third rectal adenocarcinoma. Endoscopy. 39(4). 309–313. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact